OCULAR THERAPEUTIX, INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
OCULAR THERAPEUTIX, INC (OCUL) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $14.65 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $14.65M, a 51.36% increase year-over-year.
- OCULAR THERAPEUTIX, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $15.58M, a 49.02% increase year-over-year.
- OCULAR THERAPEUTIX, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $11.69M, a 76.04% increase year-over-year.
- OCULAR THERAPEUTIX, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $9.68M, a 14.30% decline year-over-year.
- OCULAR THERAPEUTIX, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $43.18M, a 30.43% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $33.11M, a 85.74% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $17.82M, a 5.08% increase from fiscal 2022.
- OCULAR THERAPEUTIX, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $16.96M, a 13.27% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $14.65M 10-Q · filed 2026-08-03 | $30.23M derived: sum of 2 quarters · filed 2026-08-03 | |||
| 2026-03-31 | $15.58M 10-Q · filed 2026-08-03 | ||||
| 2025-12-31 | $43.18M 10-K · filed 2026-02-05 | ||||
| 2025-09-30 | $11.69M 10-Q · filed 2025-11-04 | $21.37M derived: sum of 2 quarters · filed 2026-08-03 | $31.82M derived: sum of 3 quarters · filed 2026-08-03 | ||
| 2025-06-30 | $9.68M 10-Q · filed 2026-08-03 | $20.13M derived: sum of 2 quarters · filed 2026-08-03 | |||
| 2025-03-31 | $10.46M 10-Q · filed 2026-08-03 | ||||
| 2024-12-31 | $33.11M 10-K · filed 2026-02-05 | ||||
| 2024-09-30 | $6.64M 10-Q · filed 2025-11-04 | $17.93M derived: sum of 2 quarters · filed 2025-11-04 | $25.91M derived: sum of 3 quarters · filed 2025-11-04 | ||
| 2024-06-30 | $11.29M 10-Q · filed 2025-11-04 | $19.27M derived: sum of 2 quarters · filed 2025-11-04 | |||
| 2024-03-31 | $7.98M 10-Q · filed 2025-11-04 | ||||
| 2023-12-31 | $17.82M 10-K · filed 2026-02-05 | ||||
| 2023-09-30 | $4.51M 10-Q · filed 2024-11-14 | $8.93M derived: sum of 2 quarters · filed 2024-11-14 | $13.50M derived: sum of 3 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $4.41M 10-Q · filed 2024-11-14 | $8.98M derived: sum of 2 quarters · filed 2024-11-14 | |||
| 2023-03-31 | $4.57M 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | $16.96M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | $4.24M 10-Q · filed 2023-11-07 | $8.52M derived: sum of 2 quarters · filed 2023-11-07 | $12.73M derived: sum of 3 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $4.28M 10-Q · filed 2023-11-07 | $8.49M derived: sum of 2 quarters · filed 2023-11-07 | |||
| 2022-03-31 | $4.21M 10-Q · filed 2023-11-07 | ||||
| 2021-12-31 | $14.98M 10-K · filed 2024-03-11 | ||||
| 2021-09-30 | $3.76M 10-Q · filed 2022-11-07 | $8.05M derived: sum of 2 quarters · filed 2022-11-07 | $11.14M derived: sum of 3 quarters · filed 2022-11-07 | ||
| 2021-06-30 | $4.29M 10-Q · filed 2022-11-07 | $7.38M derived: sum of 2 quarters · filed 2022-11-07 | |||
| 2021-03-31 | $3.09M 10-Q · filed 2022-11-07 | ||||
| 2020-12-31 | $7.53M 10-K · filed 2023-03-06 | ||||
| 2020-09-30 | $1.94M 10-Q · filed 2021-11-08 | $3.76M derived: sum of 2 quarters · filed 2021-11-08 | $5.43M derived: sum of 3 quarters · filed 2021-11-08 | ||
| 2020-06-30 | $1.83M 10-Q · filed 2021-11-08 | $3.49M derived: sum of 2 quarters · filed 2021-11-08 | |||
| 2020-03-31 | $1.67M 10-Q · filed 2021-11-08 | ||||
| 2019-12-31 | $8.76M 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $3.17M 10-Q · filed 2020-11-05 | $4.86M derived: sum of 2 quarters · filed 2020-11-05 | $6.81M derived: sum of 3 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $1.70M 10-Q · filed 2020-11-05 | $3.64M derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-31 | $1.94M 10-Q · filed 2020-11-05 | ||||
| 2018-12-31 | $7.48M 10-K · filed 2020-03-12 | ||||
| 2018-09-30 | $1.87M 10-Q · filed 2019-11-12 | $3.70M derived: sum of 2 quarters · filed 2019-11-12 | $5.53M derived: sum of 3 quarters · filed 2019-11-12 | ||
| 2018-06-30 | $1.83M 10-Q · filed 2019-11-12 | $3.66M derived: sum of 2 quarters · filed 2019-11-12 | |||
| 2018-03-31 | $1.83M 10-Q · filed 2019-11-12 | ||||
| 2017-12-31 | $7.32M 10-K · filed 2020-03-12 | ||||
| 2016-12-31 | $5.96M 10-K · filed 2019-03-07 | ||||
| 2015-12-31 | $4.64M 10-K · filed 2018-03-08 | ||||
| 2014-12-31 | $2.64M 10-K · filed 2017-03-10 | -$2.64M 10-K · filed 2015-03-20 | |||
| 2013-12-31 | $476.00K 10-K · filed 2016-03-10 | -$476.00K 10-K · filed 2015-03-20 | |||
| 2012-12-31 | -$243.00K 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |